Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

NovoCure Limited - Ordinary Shares (NQ:NVCR)

12.92 -0.19 (-1.45%)
Delayed Quote Updated: 1:41 PM EDT, Oct 30, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about NovoCure Limited - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
21 22 Next >
News headline image
NovoCure Q3 Earnings Call Highlights ↗
NovoCure (NASDAQ:NVCR) reported third-quarter 2026 net revenue of $193 million, up 16% from a year earlier, as growth in its Optune Gio business and an expanding launch of Optune Lua in Japan helped... 
Via MarketBeat
Topics Earnings
News headline image
NovoCure (NVCR) Q3 2026 Earnings Call Transcript ↗
Record revenue and positive adjusted EBITDA in four years mark profitability shift. 
Via The Motley Fool
Topics Earnings
Novocure (NASDAQ:NVCR) Q3 Results Beat Estimates as Raised Outlook Lifts Stock ↗
Via Chartmill
News headline image
Novocure Reports Third Quarter 2026 Financial Results and Raises 2026 Guidance
From Novocure
Via Business Wire
Novocure (NASDAQ:NVCR) Rallies 13% on Earnings Beat as High Growth Stock Nears Profitability ↗
Via Chartmill
Topics Earnings
News headline image
Novocure to Evaluate Tumor Treating Fields Therapy with VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, to Treat Pancreatic Cancer Through Clinical Trial Collaboration and Supply Agreement
From Novocure
Via Business Wire
News headline image
Novocure’s Optune Pax® Receives Approval in Japan for the Treatment of Unresectable Locally Advanced Pancreatic Cancer
From Novocure
Via Business Wire
News headline image
Novocure to Report Third Quarter 2026 Financial Results
From Novocure
Via Business Wire
News headline image
NovoCure Eyes Glioblastoma Growth, Cancer Launches and EBITDA Break-Even ↗
NovoCure (NASDAQ:NVCR) outlined its strategy for returning its glioblastoma franchise to growth, expanding launches in pancreatic and lung cancer, and moving toward profitability during the Morgan... 
Via MarketBeat
News headline image
Novocure Announces Upcoming Investor Events
From Novocure
Via Business Wire
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
Gainers NovoCure (NASDAQ:NVCR) shares moved upwards by 27.7% to $19.88 during Thursday's regular session. The market value of their outstanding shares is at $1.8 billion. The company's, Q2 earnings... 
Via Benzinga
The market is filled with gapping stocks in Thursday's session. ↗
Via Chartmill
News headline image
Transcript: NovoCure Q2 2026 Earnings Conference Call ↗
NovoCure (NASDAQ:NVCR) released second-quarter financial results and hosted an earnings call on Thursday. Read the complete transcript below. This transcript is brought to you by Benzinga APIs. For... 
Via Benzinga
Topics Earnings
News headline image
NovoCure Q2 Earnings Call Highlights ↗
NovoCure (NASDAQ:NVCR) reported record second-quarter 2026 net revenue and active patient levels, with management pointing to growth across its approved products and improved expense discipline as it... 
Via MarketBeat
Topics Earnings
News headline image
Novocure Reports Second Quarter 2026 Financial Results
From Novocure
Via Business Wire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NovoCure Limited - NVCR
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NovoCure Limited - NVCR
From Pomerantz LLP
Via GlobeNewswire
News headline image
Novocure to Report Second Quarter 2026 Financial Results
From Novocure
Via Business Wire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NovoCure Limited - NVCR
From Pomerantz LLP
Via GlobeNewswire
News headline image
Novocure’s Optune Pax® Receives CE Mark for the Treatment of Locally Advanced Pancreatic Cancer
From Novocure
Via Business Wire
News headline image
HeartFlow vs. NovoCure: Which Emerging Healthcare Stock Is a Better Buy in 2026? ↗
AI-powered diagnostics meet global oncology innovation as two medical disruptors post strong revenue growth, yet face distinct risk and valuation profiles. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
NovoCure vs. Omeros: Which Emerging Pharmaceutical Stock Is a Better Buy in 2026? ↗
Both companies target serious health challenges, but their financials and risk profiles reveal sharply different paths for growth-focused investors. 
Via The Motley Fool
News headline image
NVCR Investors Have Opportunity to Join NovoCure Limited Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
News headline image
Amgen vs. NovoCure: Which Health Care Stock Is a Better Buy in 2026? ↗
Amgen posts strong profits and cash flow, while NovoCure pursues growth with a direct-to-patient cancer therapy model and leaner balance sheet. 
Via The Motley Fool
Thursday's session: gap up and gap down stocks ↗
Via Chartmill
These stocks that are showing activity before the opening bell on Thursday. ↗
Via Chartmill
News headline image
Novocure Announces Topline Data from the Phase 3 TRIDENT Trial Evaluating Earlier Use of Tumor Treating Fields Therapy in Newly Diagnosed Glioblastoma
From Novocure
Via Business Wire
News headline image
CEO Sells 34K Shares of Biotech Stock, Valued at $615,000, According to Latest SEC Filing ↗
This oncology device innovator, known for its tumor-treating technologies, reported a notable insider sale in its latest SEC filing. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Vericel Revenue Jumped 20%. One Biotech Investor Just Reported Adding $63 Million More ↗
Vericel develops cell therapies for cartilage repair and burn care, serving hospitals and clinics across the United States. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
3 Overlooked Stocks Set to Soar in 2026 ↗
These relatively small biotechs have recent catalysts that haven't yet been fully priced into their stocks. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
21 22 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.